Ignite Creation Date:
2024-05-06 @ 4:14 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04924179
Status:
UNKNOWN
Last Update Posted:
2022-08-17
First Post:
2021-06-03
Brief Title:
Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC
Sponsor:
Huazhong University of Science and Technology
Organization:
Huazhong University of Science and Technology
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-06-01
Start Date Type:
ACTUAL
Primary Completion Date:
2022-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-06
Completion Date Type:
ESTIMATED
First Submit Date:
2021-06-03
First Submit QC Date:
June 7 2021
Study First Post Date:
2021-06-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-08-15
Last Update Post Date:
2022-08-17
Last Update Post Date Type:
ACTUAL